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Abstract
C3a and C5a anaphylatoxins are proinflammatory polypeptides released during complement
activation. They exert their biological activities through interaction with two G protein-coupled
receptors named C3aR and C5aR, respectively. In the brain, these receptors are expressed on glial
cells, and some recent data have suggested that anaphylatoxins could mediate neuroprotection. In
this study, we used RT-PCR and ribonuclease protection assays (RPA) to investigate the role of
anaphylatoxins on neurotrophin expression by the human glioblastoma cell line T98G and by rat
astrocytes. Our data show that for both cell types, anaphylatoxins upregulate expression of NGF
mRNA. This response depended on a G protein-coupled pathway since pre-treatment of cells with
pertussis toxin (PTX) completely blocked NGF mRNA increases. This effect was anaphylatoxin-
specific since pre-incubation with anti-C3a or anti-C5aR antibodies abolished the effects of C3a and
C5a, respectively. The regulation of NGF mRNA by anaphylatoxins was not accompanied by
translation into protein expression, but there was a significant synergic effect of anaphylatoxins/IL-
1b costimulation. Our demonstration of involvement of anaphylatoxins in the NGF release process
by astrocytes suggests that C3a and C5a could modulate neuronal survival in the CNS.
Introduction
Injury in the CNS produces a multi-faceted, complex cas-
cade of events that includes immunological changes such
as activation of the complement system and generation of
antibodies, release of pro-inflammatory cytokines and
chemokines, and production of reactive oxygen species
leading to oxidative stress. Activation of the complement
(C) system leads to release of various fragments among
which the anaphylatoxins, C3a and C5a, are two proin-
flammatory polypeptides. C3a and C5a, which are liber-
ated through cleavage of C3 and C5 by C convertases,
exert their biological activities by binding to two G pro-
tein-coupled receptors named C3aR and C5aR, respec-
tively [1]. There is evidence that C biosynthesis occurs in
the CNS and all components of the C system can be syn-
thesized locally by astrocytes, microglia and neurons [2].
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Complement functions to eliminate intruding pathogens.
However, there is now considerable evidence that
increased complement synthesis and uncontrolled com-
plement activation in the CNS contribute to pathological
changes in the brain. Intrathecal complement activation
has been shown to occur in multiple sclerosis, Alzheimer's
disease, bacterial meningitis, stroke and other brain dis-
eases [3,4]. Inflammatory reactions in these disorders are
also associated with expression of pro-inflammatory
cytokines, including IL-1β, TNF-α, IL-6, IFN-γ and IL-8.
Excess expression of these cytokines can result in the
destruction of the body's own cells, particularly neurons.
Several classes of neurons rely on neurotrophic factors,
including nerve growth factor (NGF), for their survival
and maintenance of function. Neurotrophins have many
important physiological roles during and after CNS devel-
opment [5]. Moreover, in brain disorders such as Alzhe-
imer's disease increasing levels of endogenous NGF may
be beneficial [6,7]. NGF is produced predominantly by
neurons under normal physiological conditions; whereas
astrocytes become the major site of NGF synthesis in the
CNS during periods of rapid glial proliferation or after
injury in the adult brain, [8-11]. Previous studies have
shown that NGF secretion from astrocytes is modulated
by various factors including glial cell growth, neurotrans-
metters and cytokines [12-14]. IL-1β is one of the most
potent stimulators of NGF secretion in cultured neonatal
astrocytes [15,16,14]. In normal, healthy brain, expres-
sion of IL-1β and its mRNA are very low [17], but these
increase markedly in response to local inflammation,
injury, or disease states such as Alzheimer's disease and
stroke [18-21].
There is now growing evidence that complement, and
more specifically the anaphylatoxins, could participate in
neuroprotection in the brain [22-24]. To further examine
the potential roles of C3a and C5a in the CNS, we exam-
ined the release of NGF by astrocytes upon stimulation
with anaphylatoxins, which thus may participate to neu-
roprotection.
Materials and methods
Reagents, cytokines and antibodies
PTX, human recombinant C5a, and IL-1β were purchased
from Sigma, St Quentin Fallavier, France. Anti-C3a mon-
oclonal antibody (G10) and anti-C5aR antibody, used to
block the effect of C3a and C5aR, respectively, have been
characterized previously [25,26].
Human C3a was generated by activation of C, and puri-
fied as previously described [25].
Multiple-Associated-Peptide (MAP)-C3a and (MAP)-C5a
peptides, corresponding to the C-terminal part of the ana-
phylatoxins (amino acids correspond 64–77 for C3a and
61–74 for C5a, respectively), attached to a poly-lysine
comb (eight peptidic monomers) were synthesized by
solid phase synthesis (Applied Biosystem) and were puri-
fied by reverse phase HPLC. Sequences were ascertained
by amino acid analysis. The concentrations of MAP pep-
tides were calculated with the whole Molecular Mass of
the MAP peptide.
Cell culture
The human glioblastoma cell line T98G was obtained
from American Type Culture Collection (Rockville, MD,
USA). These cells were screened routinely using a Myco-
plasma Detection Kit (Boehringer Mannheim, Meylan,
France) to ensure that they were mycoplasma free. Cells
were grown in Ham's F12 culture medium (Biowhittaker,
Emerainville, France) supplemented with 1% penicillin
and streptomycin (Life Technologies, Cergy-Pontoise,
France), and 10% heat-inactivated fetal calf serum (Life
Technologies).
Primary astrocytes were prepared from brain of new-born
rats and cultivated as previously described [27]. All stimu-
lations with anaphylatoxins or IL-1β were realized in
medium without serum (Ultradoma, Biowhittaker). The
astrocyte marker glial fibrillary acidic protein (GFAP) was
detected by flow cytometry in 95–97% of these cells. CR3-
positive cells were not detected in primary astrocyte cul-
tures using the OX42 monoclonal antibody (ECACC,
Sigma) and analysis by flow cytometry.
RNA extraction
Total RNA was extracted from cells using a guanidium iso-
thyocyanate method followed by ultracentrifugation onto
a cesium chloride cushion. Total RNA (50 µg) was treated
for 20 min at 37°C with 90 U of RQ-1 RNase- free DNase
(Promega, Charbonnières, France) in 100 µl of buffer (40
mM Tris-HCl pH 8, 10 mM NaCl, 6 mM MgCl2 and 10
mM CaCl2) and 200 U of RNasin ribonuclease inhibitor
(Promega) to remove all traces of contaminating genomic
DNA.
PCR primers
Human NGF and glyceraldehyde 3-phosphate deshydro-
genase (GAPDH) primers were chosen according to their
cDNA sequences reported in EMBL Data Library under
Accession Numbers X52599 and M33197. Their
sequences from 5' to 3' were as followed: NGF sense [AGG
TGC ATA GCG TAA TGT CC], NGF antisense [CCT TGA
CAA AGG TGT GAG TC], GAPDH sense [TGC CAT CAA
CGA CCC CTT CA] and GAPDH antisense [TGA CCT TGC
CCA CAG CCT TG]. The theoretical size was 642 pb for
NGF and 549 pb for GAPDH.Journal of Neuroinflammation 2006, 3:8 http://www.jneuroinflammation.com/content/3/1/8
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RT-PCR
Reverse transcription was carried out for 60 min at 37°C
in 30 µl (final volume) with 2 µg of total RNA, 20 U RNa-
sin (Promega), 250 pmol random hexamer primers
pd(N)6 (Pharmacia Biotech, Orsay, France), 1 mM dNTPs
(Pharmacia), 5 mM DTT and 400 U Moloney Murine
Leukemia Virus Reverse Transcriptase (MMLV)-RT (Life
Technologies) in the reaction buffer (250 mM Tris-HCl,
375 mM KCl, 15 mM MgCl2). The reaction mixture was
then heated to inactivate the MMLV-RT. PCR was carried
out with 5 µl of cDNA pool, in 50 µl final volume with 1.5
mM MgCl2, 200 µM de (dNTPs), 100 pmol of NGF prim-
ers and 2 U of Taq DNA polymerase (Life Technologies)
in the reaction buffer (20 mM Tris-HCl, 0.1 mM d'EDTA,
1 mM DTT). The PCR steps used were: denaturation for 4
min at 94°C, 25 to 30 cycles [denaturation 94°C for 40 s,
annealing at 57°C for 50 s and extension at 72°C for 90
s], and final elongation step at 72°C for 10 min. PCR was
performed in a Hybaid Omnigene thermocycler (Sch-
leicher and Schuell, Céra-labo, Ecqueville, France. The
absence of contaminant DNA was routinely checked by
RT-PCR on negative control samples in which either the
RNA samples were replaced with sterile water, or the
MMLV-RT was omitted. For semi-quantitative RT-PCR,
PCR was realized with a GAPDH:NGF primers ratio of
1:75 and 1 µCi [33P]dATP (Redivue, Amersham, Les Ulis,
France). Experiments were conducted in which total RNA
was amplified with different cycle numbers for GAPDH
and NGF primers to assure that RNA bands after amplifi-
cation were detected within the linear part of the amplify-
ing curves. Autoradiograms were analyzed using Lecphor
image analyzer (Biocom, Les Ulis, France). Results are
expressed as a ratio of the area of the band of interest to
the mean of the area of the housekeeping gene band. The
NGF mRNA value, from unstimulated cells, was set to one
unit arbitrarily and values for the other samples were cal-
culated relative to this.
Multiprobe RNase protection assay (RPA)
After total RNA isolation, RPA was performed using the
RiboQuant Multiprobe RNase Protection Assay System
(BD PharMingen, Le Pont de Claix, France), according to
the manufacturer's instructions. Briefly, the provided rat
neurotrophin template set (rNT-1) contained probes for
six neurotrophins (NGF, brain-derived neurotrophic fac-
tor (BDNF), glial cell line-derived neurotrophic factor
(GDNF), ciliary neurotrophic factor (CNTF), neuro-
trophin-3 (NT-3) and NT-4) and two housekeeping genes
(GAPDH and L-32). To synthesize anti-sense cRNA, the
probes were labeled with [32P]α UTP (800 Ci/mmol, 10
mCi/ml; Amersham) using a transcription kit according to
the manufacturer's manual. Ten micrograms of each sam-
ple were used for hybridization with the anti-sense RNA
probe at 56°C for 12–16 h, followed by digestion of free
probe and unprotected ssRNA with RNase solution
(RNase A plus RNase T1). The remaining dsRNA was then
extracted in chloroform-isoamyl alcohol (50:1) and was
precipitated with ethanol and separated on a 7 M urea/6%
polyacrylamide gel. A part of the undigested probe was
used as marker standard. After drying, the gel was placed
in an exposure cassette with a phosphor screen for 48 h.
Bands were detected by phosphorimaging using Image-
Quant software (Molecular Dynamics). A standard curve
plotted with the undigested probe markers was used to
identify the bands of various genes in the experimental
samples. Results are expressed as a ratio of the volume of
the band of interest to the mean of the volumes of the
bands for the housekeeping genes. The neurotrophin
mRNA value, from unstimulated cells, was set to one unit
arbitrarily and values for the other samples were calcu-
lated relative to this.
Enzyme-linked immunosorbent assay (ELISA)
Concentrations of NGF protein in culture supernatant
samples were determined by a specific sensitive ELISA
(sensitivity 15.6 pg/ml): NGF Emax Immunoassay System
(Promega), according to manufacturer's instructions. The
absorbance was measured at A450 nm with a plate reader
(Labsystems iEMS Reader MF) and NGF content in the
samples was determined by comparison with a NGF
Expression of NGF mRNA by unstimulated T98G cells ana- lyzed by RT-PCR Figure 1
Expression of NGF mRNA by unstimulated T98G cells analyzed by 
RT-PCR. Lane L represents the size markers (100 bp ladder) 
and lane 1 the NGF amplicon (642 bp) with (+) or without (-
) the MMLV-RT.Journal of Neuroinflammation 2006, 3:8 http://www.jneuroinflammation.com/content/3/1/8
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standard curve. The level of NGF in the culture superna-
tants was expressed as pg/ml per 106 cells.
Statistical analysis
Data are expressed as mean ± SEM. Statistical analysis was
performed using Student's t test. Differences were consid-
ered statistically significant at p < 0.05.
Results
C3a and C5a anaphylatoxins increase NGF mRNA 
expression in human glioblastoma cell line T98G
In a first approach, we studied NGF mRNA expression in
the human glioblastoma cell line T98G. This cell line
expresses C3a and C5a receptors [28,29] and has been
shown to respond to anaphylatoxin stimulations, induc-
ing IL-6 mRNA expression [30].
Expression of NGF mRNA was first analyzed in unstimu-
lated T98G cells by RT-PCR, and PCR products were visu-
alized by agarose gel electrophoresis and staining with
ethidium bromide (Fig. 1). A unique 642 bp band was
observed, corresponding to the expected size of NGF
amplicon. Thus, unstimulated T98G cells constitutively
expressed NGF mRNA. No amplification product
appeared for the negative control where MMLV-RT was
omitted.
T98G cells were then stimulated by MAP-C3a or MAP-C5a
(10-8M), two strong peptidic anaphylatoxin analogs and
total RNA was extracted after different stimulation times
(2 h, 4 h, 6 h, 12 h and 24 h). NGF mRNA expression was
then analyzed using semi-quantitative RT-PCR using
GAPDH as internal standard. Results are presented as rel-
ative fold-increase over control (unstimulated cells) (Fig.
2). NGF mRNA expression was increased by 3.2 fold after
2 h of stimulation by MAP-C3a and by 2.9 fold after 4 h
for MAP-C5a. Upregulation of NGF mRNA expression
induced by MAP-C3a or MAP-C5a was also observed fol-
lowing stimulation using human purified C3a and recom-
binant C5a. T98G cells were stimulated with C3a or C5a
(10-8M) and NGF mRNA expression was assessed by semi-
quantitative RT-PCR. After 4 h of stimulation, NGF mRNA
level was increased by 1.8 fold and 2.2 fold, respectively
(Fig. 3).
Anaphylatoxin-upregulated NGF mRNA expression is 
dose-dependent and specific
T98G cells were stimulated with MAP-peptides or ana-
phylatoxins in a range of 10-13M to 10-7M. Total RNA was
extracted after 4 h of stimulation and NGF mRNA expres-
sion was measured. From 10-10M to 10-8M, we observed a
linear relationship between the NGF mRNA expression
and the concentration of the different agonists, showing
dose-dependent increases in NGF mRNA (data not
shown). A significant response was obtained when con-
centrations reached 10-10 M for MAP-peptides and 10-9M
for anaphylatoxins with comparable activities for C3a and
C5a derivatives; the effect was maximum at 10-8 M for
both agonist types. These concentrations ranges match
those recorded in previous studies on astrocytes [30,31].
Expression of NGF mRNA after stimulation of T98G celsl by MAP-C3a (A) or MAP-C5a (B) (10-8M) Figure 2
Expression of NGF mRNA after stimulation of T98G celsl by MAP-C3a (A) or MAP-C5a (B) (10-8M). RNA was extracted after 2 h, 4 
h, 6 h, 12 h and 24 h of stimulation and analyzed by semi-quantitative RT-PCR using GAPDH as internal standard. Bars repre-
sent the mean ± SEM for three independent experiments. **, p < 0.01, statistically significant compared with control as deter-
mined by Student's t test (NS = non stimulated cells).Journal of Neuroinflammation 2006, 3:8 http://www.jneuroinflammation.com/content/3/1/8
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In order to ascertain the specificity of anaphylatoxin
upregulation of NGF mRNA, we tried to block their effect
using specific antibodies. For this experiment, we used
two antibodies that did not cross-react, anti-C3a did not
inhibit the C5a effect and anti-C5aR did not modify the
C3a effect (data not shown). Pre-incubation of C3a ana-
phylatoxin with an anti-C3a antibody (1µg/ml) during 30
min completely blocked the upregulation of NGF gene
expression induced by C3a alone (Fig. 3). Similarly, when
cells were pre-incubated during 30 min with an anti-C5aR
antibody (1µg/ml) before C5a stimulation, the C5a-
induced NGF mRNA upregulation was abolished (Fig. 3).
C3a and C5a anaphylatoxins are known to bind to dis-
tinct receptors that are both functionally coupled to G
proteins [32,33]. To confirm that MAP-peptide stimula-
tion, leading to upregulation of NGF mRNA, acts through
the G protein coupled receptor, T98G cells were pre-incu-
bated with Pertussis toxin (PTX) (200 ng/ml) for 4 h prior
to MAP-peptide stimulation. After 4 h of either stimula-
tion by anaphylatoxin agonists or no stimulation, the
level of NGF mRNA was quantified. PTX alone had no
effect on the constitutive NGF expression, but pre-treat-
ment of cells by PTX completely abrogated the upregula-
tion of NGF mRNA expression induced by anaphylatoxin
agonists (Fig. 4).
MAP-C3a and MAP-C5a upregulate NGF mRNA 
expression by rat primary astrocytes
To confirm previous results obtained with T98G, we
examined neurotrophin expression by rat primary astro-
cytes stimulated by MAP-C3a or MAP-C5a. Variation of
neurotrophin expression was assessed by the sensitive
RPA technique. In the same series of experiments, we
determined NGF, BDNF, CNTF, GDNF, NT-3 and NT-4
mRNA expression.
We first observed that unstimulated rat astrocytes consti-
tutively express NGF, BDNF and CNTF mRNA (Fig. 5left);
GDNF, NT-3 and NT-4 mRNA were only detected on over-
exposed autoradiograms (not shown). Rat astrocytes were
then stimulated by MAP-C3a or MAP-C5a (10-8M) and
total RNA was extracted after different stimulation times
(2 h, 4 h, 6 h, 12 h and 24 h). mRNA expression was then
determined using GAPDH and L-32 as internal standards.
Results are presented as relative fold-increase over control
(unstimulated cells) (Fig. 5right). MAP-peptide stimula-
Influence of toxin pertussis (PTX) on the NGF mRNA pro- duction by T98G cells following stimulation with MAP-C3a  or MAP-C5a (10-8M) Figure 4
Influence of toxin pertussis (PTX) on the NGF mRNA production 
by T98G cells following stimulation with MAP-C3a or MAP-C5a 
(10-8M). Cells were pre-incubated for 4 h with PTX (200 ng/
ml) and then stimulated by MAP-C3a or MAP-C5a for 4 h. 
Cells were also incubated with PTX alone. Total RNA was 
extracted and RT-PCR was performed. Bars represent the 
mean ± SEM for three independent experiments.**, p < 0.01, 
statistically significant difference compared with non-stimu-
lated cells (NS) as determined by Student's t test; #, p < 0.05, 
statistically significant difference compared with cells stimu-
lated with MAP-peptides as determined by Student's t test.
Expression of NGF mRNA after stimulation of T98G cell line  by C3a or C5a anaphylatoxins (10-8M)- Effect of pre-incuba- tion with anti-C3a or anti-C5aR antibodies Figure 3
Expression of NGF mRNA after stimulation of T98G cell line by 
C3a or C5a anaphylatoxins (10-8M)- Effect of pre-incubation with 
anti-C3a or anti-C5aR antibodies. C3a anaphylatoxin was pre-
incubated for 30 min with an anti-C3a antibody (diluted 1/
100); or cells were pre-incubated for 30 min with an anti-
C5aR antibody (diluted 1/100) before a 4 h stimulation by 
C3a or C5a (10-8M). Total RNA was extracted and RT-PCR 
was performed. Bars represent the mean ± SEM for three 
independent experiments. *, p < 0.05, statistically significant 
difference compared with non-stimulated cells (NS) as deter-
mined by Student's t test; #, p < 0.05, statistically significant 
difference compared with cells stimulated with C5a as deter-
mined by Student's t test.Journal of Neuroinflammation 2006, 3:8 http://www.jneuroinflammation.com/content/3/1/8
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tions of astrocytes induced an increase of NGF mRNA,
multilplied by 2.1 after 2 h stimulation with MAP-C3a
and by 2.3 after 4 h with MAP-C5a. MAP-peptide stimula-
tion did not increase BDNF or CNTF mRNA and did not
increase the level of expression of GDNF, NT-3 nor NT-4
mRNA. These experiments were repeated three times and
were reproducible.
Anaphylatoxin stimulation increased NGF secretion by 
T98G cell line
To confirm that increases in mRNA translate into NGF
secretion, we performed ELISA. The supernatants of stim-
ulated T98G cells were collected after 12 h, 24 h, 48 h and
72 h stimulation by either MAP-peptides or anaphylatox-
ins (10-8M) and the concentration of NGF protein was
analyzed by specific sensitive ELISA. A basal level of NGF,
produced by T98G cells, was observed (133 ± 47 pg/ml/
106 cells) and anahylatoxins did not significantly increase
this NGF secretion (Fig. 6). After 48 h of stimulation, NGF
levels reached 212 ± 70 pg/ml/106 cells for C3a, 268 ± 56
pg/ml/106 cells for C5a, 287 ± 64 pg/ml/106 cells for MAP-
C3a and 225 ± 68 pg/ml/106 cells for MAP-C5a. Although
we observed constantly increased NGF concentrations in
supernatants of stimulated cells, these increases were not
statistically significant even at 48 h post-stimulation.
Synergistic effect of anaphylatoxins and IL-1 beta on NGF 
secretion
Anaphylatoxins are generated in an inflammatory context
where cytokines are also released, especially IL-1β. Thus,
we investigated the effects of anaphylatoxin/IL-1β co-
stimulation on NGF release. First, we measured the release
of NGF in supernatants of T98G cells after 48 h of stimu-
lation by various doses of IL-1β in order to determine the
maximum concentration of IL-1β that did not increase
NGF secretion (Fig. 7A). We observed that concentrations
of IL-1β below 0.5 U/ml did not enhance NGF secretion
by T98G cells. Then, we co-stimulated T98G cells over 48
h with IL-1β (0.5 U/ml) and with C3a, C5a, MAP-C3a or
MAP-C5a (10-8M). The resultant NGF levels are reported
in Fig. 7B. Co-stimulation with IL-1β led to high increases
of NGF secretion: from 170 ± 42 pg/ml/106 cells for IL-1β
to 388 ± 56 pg/ml/106 cells for IL-1β +C3a, to 443 ± 60 pg/
ml/106 cells for IL-1β +C5a, to 486 ± 54 pg/ml/106 cells
for IL-1β +MAP-C3a and to 453 ± 57 pg/ml/106 cells for
IL-1β +MAP-C5a. These results show a significant synergic
Expression of neurotrophic factors by rat primary astrocytes stimulated by MAP-C3a or MAP-C5a (10-8M) Figure 5
Expression of neurotrophic factors by rat primary astrocytes stimulated by MAP-C3a or MAP-C5a (10-8M). Autoradiogramm of neuro-
trophin mRNA expression by unstimulated rat primary astrocytes is shown on the left panel: Lane 1 represents the Multi-
Probe Template Set not treated with RNases and Lane 2 the neurotrophin mRNA expression by unstimulated rat primary 
astrocytes. Note that each probe band (Lane 1) migrates slower than its protected band (Lane 2); this is due to flanking 
sequences in the probe that are not protected by mRNA. RNA was then extracted after 2 h, 4 h, 6 h, 12 h and 24 h of stimu-
lation and analyzed using L-32 and GAPDH as internal standards. On the right panel, results are represented as histograms and 
expressed as relative fold increase over control (NS = non-stimulated cells). This is a representative graph of n = 3 independ-
ent experiments.Journal of Neuroinflammation 2006, 3:8 http://www.jneuroinflammation.com/content/3/1/8
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effect of anaphylatoxin and IL-1β stimulation on NGF
production. To confirm these results obtained with T98G
cells, we examined NGF expression by rat primary astro-
cytes co-stimulated with MAP-peptides and IL-1β (0.5 U/
ml/10-8M) over 48 h. As expected, MAP stimulation did
not induce NGF release. but the MAP-peptides and IL-1β
synergistically stimulated astrocyte NGF protein expres-
sion, as illustrated in figure 7C with MAP-C3a and IL-1β
co-stimulation.
Discussion
These experiments aimed at showing the potential role of
anaphylatoxins to produce neurotrophins in order to pro-
tect neurons from injury. This hypothesis comes from the
observation that C3a has neuroprotective effects against
NMDA-induced neuronal death only in mixed cultures of
neurons and astrocytes [34]. We postulated that this indi-
rect effect of C3a on neuroprotection could be due, at least
in part, to neurotrophin release by astrocytes.
It is well established that complement is produced in the
brain, that complement activation permits the release of
the anaphylatoxins, C3a and C5a; and that these signal
through their respective receptors, C3aR and C5aR, since
stimulation of glial cells by anaphylatoxins can increase
cytokine production [24,30,31]. The roles of anaphylatox-
ins on brain cells remain ill-characterized and they may
have functional roles independent of their classical role as
mediators of inflammation. Altought complement has
been implicated as a mediator of neuroinflammation and
neurodegeneration, as in Alzheimer's disease [35,36],
some inflammatory mediators, in particular the anaphyla-
toxins, are reported to have neuroprotective role.
In the present study, we sought to obtain further clues on
the potential roles of C3a and C5a anaphylatoxins in neu-
roprotection by investigating the effects of C3a and C5a in
parallel with their peptidic analogs, MAP-C3a and MAP-
C5a on NGF release by astrocytes. Preliminary studies
were performed by RT-PCR using the human T98G cell
line. Our laboratory has previously shown that these cells
express C3aR and C5aR, and using a cell line provided
uswith homogenous material perfectly adapted for using
RT-PCR technique. Thus, we observed that stimulation of
T98G cells by anaphylatoxins induced increased expres-
sion of NGF mRNA. This upregulation was shown to be
dose-dependent as NGF mRNA expression varied with the
concentration of anaphylatoxins. Optimum concentra-
tions (10-8 M) are in agreement with previous studies
[30,31]. Pre-treatment of cells with PTX completely
blocked the effects of anaphylatoxinx and the MAP-pep-
tides, suggestong that their effects were mediated through
their specific receptors C3aR and C5aR. Pre-incubation
with anti-C3a or anti-C5aR antibodies abolished the C3a-
and C5a-induced NGF mRNA increase respectively, show-
ing that the response was specific. Thus, the NGF mRNA
increase acted via  the anaphylatoxins/anaphylatoxin
receptors and was not due to contaminants in anaphyla-
toxin preparations.
Analysis of NGF mRNA expression following anaphyla-
toxin stimulation was also studied using rat primary astro-
cytes analyzed by RPA. We showed that unstimulated rat
astrocytes constitutively express NGF, BDNF and CNTF
mRNA. Furthermore we observed a significant NGF
mRNA increase after anaphylatoxin stimulations whereas
BDNF and CNTF mRNA expression remained unchanged.
We consistently observed an increase in NGF concenta-
tion in cell supernatants following anaphylatoxin stimu-
lation compared to unstimulated cells. It appeared that
this effect was not statistically significant even for long
incubation periods (48 h). In a previous study, we showed
increased IL-8 mRNA expression [31] in response to ana-
phylatoxins, although this was not translated into secre-
tion of cytokine. This IL-8 secretion was induced by co-
stimulation of astrocytes with IL-1β and anaphylatoxins.
A synergistic effect of IL-1β with TNF-α on NGF secretion
by cultured rat astrocytes has been reported [37]. Since IL-
1β has no effect on C3aR and C5aR expression by T98G
cells [31] we investigated the effects of anaphylatoxins/IL-
1β costimulation on NGF release. We demonstrate here
significant synergetic effects of IL-1β and anaphylatoxin-
induced NGF-release. The significant increase in NGF
secretion is likely to be a result of synergistic actions of IL-
1β and anaphylatoxins since this dose of IL-1β had no
Production of NGF by T98G cells analyzed by ELISA after  incubation with C3a, C5a, MAP-C3a, MAP-C5a (10-8M) for  48 h Figure 6
Production of NGF by T98G cells analyzed by ELISA after incuba-
tion with C3a, C5a, MAP-C3a, MAP-C5a (10-8M) for 48 h. The 
concentration of NGF was measured in the supernatants and 
was expressed as pg/ml per 106 cells. Bars represent the 
mean ± SEM for three independent experiments.Journal of Neuroinflammation 2006, 3:8 http://www.jneuroinflammation.com/content/3/1/8
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Effect of anaphylatoxins/IL-1β co-stimulation on NGF release Figure 7
Effect of anaphylatoxins/IL-1β co-stimulation on NGF release. First, cells were stimulated for 48 h by a range of IL-1β concentra-
tions to determine the maximal concentration of IL-1β that did not induce NGF release by T98G cells (A). Second, T98G cells 
were co-stimulated for 48 h with sub-optimal dose of IL-1β (0.5 U/ml) as well as with C3a, C5a, MAP-C3a or MAP-C5a (10-8M) 
(B). NGF release by rat astrocytes following MAP-C3a (10-8M) and IL-1β (0.5 U/ml) co-stimulation for 48 h is shown in (C). 
The concentration of NGF was measured in the supernatants by ELISA and was expressed as pg/ml per 106 cells. Bars repre-
sent the mean ± SEM for three independent experiments. +, p < 0.05, statistically significant compared with cells stimulated 
with anaphylatoxins or MAP-peptides alone as determined by Student's t test.Journal of Neuroinflammation 2006, 3:8 http://www.jneuroinflammation.com/content/3/1/8
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effect on its own. It was established previously that ana-
phylatoxins do not induce IL-1-β expression [30] ruling
out the possibility that NGF upregulation by anaphylatox-
ins is due to an indirect effect via IL-1-β.
Our data, showing that anaphylatoxins in synergy with IL-
1β stimulate astrocyte NGF secretion, are consistent with
the hypothesis that many cell types release complement
proteins as a protective mechanism against threats to cell
viability. A previous study showed that C3a anaphyla-
toxin significantly induces NGF mRNA and protein pro-
duction in human microglia [24]. This effect was obtained
with a lower dose of C3a that that employed here. More-
over, in contrast to our results with astrocytes, C3a stimu-
lation alone was sufficient to stimulate NGF secretion by
microglia. In response to CNS injury, both microglia and
astrocytes undergo structural and functional changes in a
time-dependant manner. Microglia respond earlier than
do astrocytes, and their response is often transient,
whereas reactive astrocytes persist in their activated state.
Thus, astrocytes may in a time-dependent manner sup-
plant and continue the initial microglial NGF production.
Anaphylatoxins may play a conditioning role in this proc-
ess, allowing astrocytes to release neurotrophins in an
inflammatory context.
Conclusion
In contrast to studies showing C5a-induced apoptosis in a
human neuroblastoma cell line in vitro [38,39], recent
publications have implicated anaphylatoxins in neuro-
protection [40,22]. Thus, mice genetically deficient in
complement component C5 are more susceptible to kai-
nic acid excitotoxicity than are normal mice [41,42].
Moreover, other studies have recently shown that C5a can
directly protect neurons against glutamate neurotoxicity
[23] and that C3a has protective effects against NMDA-
induced neuronal death [34], suggesting involvement of
anaphylatoxins in neuroprotection. Our findings eluci-
date a molecular basis for such anaphylatoxin-mediated
neuroprotection, and fit well with the general concept that
anaphylatoxins released locally are involved in tissue
repair or remodelling [43].
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